Introduction
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) that increases natural production of growth hormone (GH) in the body. Tesamorelin activates GHRH receptors in somatotroph cells of the pituitary gland, resulting in increased pulsatile GH secretion and further downstream IGF-1 signalling.
The action of tesamorelin on visceral adipose tissue (VAT) has been a subject of significant scientific interest. Studies focused on how GHRH receptor activation affects visceral fat, body composition, liver fat, and other metabolic markers.
For instance, the paper “Metabolic effects of a growth hormone-releasing factor in patients with HIV” showed that a 26-week clinical study, tesamorelin exposure was associated with a reduction in visceral adipose tissue compared with placebo in participants with HIV-associated abdominal fat accumulation.
In a more recent randomized clinical trial entitled “Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation,” a reduction in visceral and liver fat was observed following six months of study exposure.
The present article will discuss the structure, mode of action, GH-IGF-1 pathway, pharmacology, clinical research, and limitations of tesamorelin. It will also distinguish clinical data from general research regarding the GHRH analogue.
Note: At Orion Peptides, we sell peptides for research purposes only!
Tesamorelin: A Quick Overview
Tesamorelin is a laboratory-made analog of human growth hormone-releasing hormone (GHRH). It has a 44-amino-acid sequence based on human GHRH, with a structural modification. The purpose behind the structural modification was to create a stabilized GHRH analog.
| Propertie | Tesamorelin |
|---|---|
| Peptide type | Synthetic GHRH analog |
| Key target | Receptor of GHRH |
| Basic pathway | GHRH → GH → IGF-1 |
| Molecular formula | C₂₂₁H₃₆₆N₇₂O₆₇S |
| Molecular weight | ~5,136 Da |
| PubChem ID | 16137828 |
| CAS number | 218949-48-5 |
| Developmental code | TH9507 |
Tesamorelin binds to and stimulates human GHRH receptors with activity similar to endogenous GHRH. This stimulates pulsatile growth hormone secretion, followed by increases in downstream IGF-1 and IGFBP-3 levels.
The peptide’s main scientific interest centers on the growth hormone–IGF-1 axis and visceral adipose tissue. Clinical research has examined how stimulating this pathway affects body composition and metabolic parameters.
For accuracy, tesamorelin should be distinguished from direct administration of growth hormone. Tesamorelin stimulates the body’s endogenous GH secretion through GHRH receptor signaling rather than supplying recombinant GH directly.
Tesamorelin Mechanism of Action
Tesamorelin functions by binding to the GHRH receptors of the somatotrophs in the pituitary gland, resulting in an increase in the release of the body’s own growth hormone, and not in GH supplementation.
The pathway can be simplified as:
Tesamorelin → GHRH receptors → GH secretion → IGF-1 production
Once growth hormone is released into the bloodstream, it acts on various tissues, including liver tissue. GH leads to the production of IGF-1, resulting in the effect of the GH-IGF-1 axis. Increased levels of IGF-1 and IGFBP-3 have been observed with tesamorelin therapy, according to the FDA pharmacodynamics data.
According to the research study, “Effects of a Growth Hormone-Releasing Hormone Analog on Endogenous GH Pulsatility and Insulin Sensitivity in Healthy Men,Tesamorelin exposure resulted in a significant increase in basal and pulsatile GH secretion, along with IGF-1 production.
This is what makes tesamorelin distinct from recombinant human growth hormone (rhGH). Tesamorelin functions by stimulating the pathway upstream, that is, through the stimulation of GHRH receptors. The pituitary gland will secrete endogenous GH.
Tesamorelin and the GH–IGF-1 Axis
The GH–IGF-1 axis plays a crucial role in the biological actions of tesamorelin. Tesamorelin induces GHRH receptor signaling in the pituitary gland and promotes endogenous growth hormone production. This hormone activates IGF-1 synthesis in the liver and other organs.
It can be inferred from this pathway why research on tesamorelin is concerned with both GH and IGF-1. In clinical trials, tesamorelin increased levels of IGF-1 along with affecting the patterns of growth hormone production. Thus, the article “Effects of a growth hormone-releasing factor in patients with HIV” noted the increase in IGF-1 during the treatment.
Furthermore, researchers considered the pathway in connection with the reduction of visceral adipose tissue (VAT). So, in a randomized trial with obese individuals who exhibited decreased secretion of GH, tesamorelin increased IGF-1 production and reduced visceral fat, but did not affect subcutaneous abdominal fat.
It should be emphasized that tesamorelin does not provide IGF-1 or recombinant GH. It stimulates the upstream GHRH pathway and induces the endogenous GH–IGF-1 signaling system.
Tesamorelin and Visceral Adipose Tissue
Another major focus of tesamorelin investigation is visceral adipose tissue (VAT). This refers to fat accumulated around the internal organs inside the abdomen and not under the skin like subcutaneous fat. Clinical studies provide the most compelling scientific evidence in this area.
In the clinical trial conducted in 2007 and entitled “Metabolic Effects of a Growth Hormone-Releasing Factor in Patients with HIV,” the study included 412 participants with HIV and excess abdominal adipose tissue who were assigned to receive tesamorelin or placebo. After 26 weeks, the study results showed that visceral adipose tissue was decreased by 15.2% in comparison with a 5.0% increase observed in the placebo group. The level of IGF-1 increased significantly in the tesamorelin-treated group.
In the randomized clinical trial entitled “Effect of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients With Abdominal Fat Accumulation” conducted six months after treatment initiation, it was noted that visceral fat was reduced by 34 cm² in the tesamorelin-treated group and increased by 8 cm² in the control group. The study also reported a non-significant reduction in liver fat.
Tesamorelin has also been studied in those without HIV. A randomized controlled study known as “Metabolic Effects of a Growth Hormone-Releasing Factor in Obese Subjects With Reduced Growth Hormone Secretion” documented a decrease in visceral fat after one year. There were no changes observed in abdominal subcutaneous fat, indicating the selectivity of tesamorelin towards visceral adipose tissue.
This study provides insight into why visceral adipose tissue is an important research outcome of tesamorelin. Nevertheless, findings from clinical studies in particular populations must not always be extrapolated to healthy people or other research settings.
What Clinical Studies Have Found
Clinical studies on tesamorelin have primarily investigated the impact of the drug on visceral adipose tissue, body composition, GH–IGF-1 axis, and metabolic parameters. Most of the studies were randomized, placebo-controlled trials, which enrolled HIV-positive patients with visceral adipose tissue accumulation.
The randomized, placebo-controlled trial “Metabolic Effects of a Growth Hormone–Releasing Factor in Patients With HIV”, which enrolled 412 participants, found that tesamorelin reduced visceral adipose tissue by 15.2% compared to the placebo group, which gained 5% of visceral fat. Additionally, the study found that tesamorelin significantly increased IGF-1 levels in the treatment group.
Another trial, “Effect of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients With Abdominal Fat Accumulation”, which also used a randomized, placebo-controlled design, found that participants receiving tesamorelin showed an average reduction of 34 cm² in visceral adipose tissue over six months. Moreover, the researchers found that tesamorelin exposure decreased their liver fat by 12%. Researchers have also investigated the effect of tesamorelin outside the context of HIV-associated lipodystrophy.
The study “Metabolic Effects of a Growth Hormone–Releasing Factor in Obese Subjects With Reduced Growth Hormone Secretion” found that tesamorelin was associated with an 11% reduction in visceral adipose tissue after 12 months. The researchers also found that tesamorelin increased IGF-1 levels, while leaving abdominal subcutaneous fat unchanged.
Furthermore, several studies have analyzed the effect of tesamorelin on fat quality. For instance, the article “Tesamorelin improves fat quality independent of changes in fat quantity” found that tesamorelin exposure was associated with changes in the density of visceral and subcutaneous adipose tissue.
The findings of these studies highlight the potential of tesamorelin in reducing visceral adipose tissue and are useful for future research. However, the results of individual trials might be different for other populations due to differences in the studied sample, duration of treatment, and other factors.
Pharmacokinetics of Tesamorelin
Tesamorelin has a short plasma half-life; however, it demonstrates prolonged biological activity due to downstream actions through the growth hormone and IGF-1 signaling. Data on the pharmacokinetic properties of the FDA-registered formulation of EGRIFTA WR state that the mean half-life time is approximately 11 minutes.
Formerly published half-life times of approximately 26 minutes for healthy individuals and 38 minutes for HIV-infected patients were based on studies involving repeated subcutaneous administration.
In a population pharmacokinetic analysis study entitled “Population Pharmacokinetic Analysis of Tesamorelin in HIV-Infected Patients and Healthy Subjects,” pharmacokinetic properties of tesamorelin were investigated in 38 people. Plasma clearance was estimated to be around 1,060 L/hour with no clinically significant pharmacokinetic effects associated with age, body mass, race, or health condition.
Tesamorelin reaches peak plasma concentrations rapidly, with a median Tmax of approximately 0.15 hours according to FDA pharmacokinetic data. According to the FDA-registered labeling, the median Tmax value is about 0.15 hours.
However, having a short circulating half-life does not imply that the compound has no biological effect. Tesamorelin causes episodic release of GH, which subsequently leads to modulation of IGF-1. Indeed, another PK/PD analysis managed to capture the described cascade involving tesamorelin, GH release, and IGF-1.
Tesamorelin vs. Other GHRH Analogs
Tesamorelin is a member of the GHRH analog family of peptides, which includes other synthetically produced compounds such as sermorelin and CJC-1295. These have similar mechanisms of action, targeting the growth hormone-releasing hormone receptors (GHRHR) on pituitary somatotroph cells.
The major differences concern peptide structure, stability, and pharmacokinetics, as well as distinct bodies of supporting research.
| Compound | GHRH receptor | Key distinction |
| Tesamorelin | Yes | Stabilized GHRH(1-44) analog with clinical research |
| Sermorelin | Yes | Short GHRH(1-29) fragment |
| CJC-1295 | Yes | Modified GHRH analog with different pharmacokinetic profiles |
Unlike sermorelin, which is constituted by the first 29 amino acids of GHRH, tesamorelin is built from the entire 44-amino-acid sequence of GHRH. CJC-1295 is a modified GHRH analog available in several formulations, including one conjugated with the Drug Affinity Complex (DAC).
All three analogs engage the GHRHR and elicit endogenous GH release, but the structural distinctions affect pharmacokinetics and pharmacodynamics, which are relevant to investigations concerned with GH pulse dynamics, receptor signaling cascades, and IGF-1 regulation. In turn, tesamorelin’s clinical research heritage provides greater confidence in its use for studies involving visceral adipose tissue, GH, and IGF-1 interactions.
Tesamorelin Safety and Research Limitations
Tesamorelin has been extensively evaluated in clinical research, but its pharmacological limitations and safety considerations remain important areas of study. According to the FDA, tesamorelin’s mechanism of action includes the risk of increased levels of IGF-1, fluid retention, glucose intolerance, hypersensitivity, and injection site reactions, among others. The most frequent side effects are arthralgia, peripheral edema, myalgia, and injection site reactions.
One should be especially aware of the possible increase in IGF-1 levels since tesamorelin is a GH–IGF-1 secretagogue, and the FDA recommends caution when using the drug due to the potential consequences of increased IGF-1 levels. The most concerning aspect of Tesamorelin’s use is its effect on glucose tolerance. Although tesamorelin clinical trials showed that the growth hormone secretagogue did not affect glucose tolerance in patients with type 2 diabetes, one trial (“Safety and metabolic effects of tesamorelin,” 2017) revealed that the drug might elevate the risk of diabetes in some individuals.
Another limitation of Tesamorelin’s use is the fact that many of the trials’ results are based on patients with HIV who have lipodystrophy. Thus, applying the same conclusions to the general population would be inappropriate. The FDA approved Tesamorelin for the treatment of upper abdominal obesity that is associated with HIV lipodystrophy, and the drug is not indicated for use in healthy patients.
Therefore, Tesamorelin’s limitations and concerns may affect its use for research purposes. Even though the drug has a well-established biological basis, the variation of patients (both healthy individuals and those with HIV), the dosage, the length of treatment, and other factors could impact the results.
Current Research Applications Of Tesamorelin
Although tesamorelin’s mechanism of action as a GHRH receptor agonist is well-established, the research into its application primarily focuses on its impact on the growth hormone (GH) signaling pathway, visceral adipose tissue, liver fat, body composition, and metabolic outcomes.
The drug’s implication in visceral adipose tissue (VAT) is the subject of numerous clinical trials, which assess the effect of tesamorelin on VAT using computed tomography. Specifically, tesamorelin preferentially targets visceral fat over abdominal subcutaneous fat. Indeed, a 2026 meta-analysis of five randomized controlled trials found that tesamorelin was associated with significant decreases in visceral adipose tissue, hepatic fat, trunk fat, and waist circumference, alongside an increase in lean body mass
The implications of tesamorelin on fat reduction in the liver and metabolic health were also subject to investigation. Specifically, the article “Effect of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients With Abdominal Fat Accumulation” reports that tesamorelin exposure was associated with reductions in both visceral adipose tissue and liver fat over six months.
The other study, namely “ Tesamorelin improves fat quality independent of changes in fat quantity,” demonstrated that tesamorelin preferentially alters adipose tissue quality rather than quantity in the participants who responded positively to the therapy.
The research into the impact of tesamorelin also includes GH–IGF-1 signaling, glucose metabolism, lipid profile, and safety evaluation. In general, investigations cover the basic understanding of GHRH’s role in GH signaling. The research questions primarily guide the clinical trials conducted with tesamorelin to date. Therefore, the main topics of scientific research utilizing tesamorelin include GHRH, GH, IGF-1, adipose tissue, and liver fat. However, the results of studies conducted with HIV patients cannot be automatically extrapolated to the general population of healthy subjects or other demographics.
Tesamorelin: Clinical Status and Research Limitations
Tesamorelin has an established clinical history, but its approved use is specific and limited. The FDA approved tesamorelin in 2010, and the current EGRIFTA WR label indicates it for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. It is not indicated for general weight-loss management.
Research also has important limitations. Much of the clinical evidence comes from people with HIV-associated lipodystrophy, so results may not apply to healthy individuals or other populations.
Tesamorelin also increases GH and IGF-1 signaling, which requires careful study. The FDA label warns about elevated IGF-1, fluid retention, glucose intolerance or diabetes, hypersensitivity reactions, and possible malignancy-related concerns. Long-term cardiovascular safety has also not been established.
For research purposes, these limitations matter. Tesamorelin has strong evidence for its GHRH receptor activity and effects on visceral adipose tissue, but its findings should remain tied to the populations, formulations, and endpoints studied in clinical research.
FAQs
1. What is tesamorelin?
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). It activates GHRH receptors and stimulates endogenous growth hormone secretion.
2. How does tesamorelin work?
Tesamorelin activates GHRH receptors on pituitary cells. This increases GH release and subsequently raises IGF-1, creating a downstream GH–IGF-1 signaling response.
3. Is tesamorelin the same as growth hormone?
No. Tesamorelin stimulates the body’s own GH secretion, while recombinant growth hormone supplies GH directly. This difference is central to their pharmacological profiles.
4. What is tesamorelin mainly studied for?
Clinical research has focused heavily on visceral adipose tissue, particularly in people with HIV-associated abdominal fat accumulation. Randomized trials have reported significant reductions in visceral fat compared with placebo.
5. Does tesamorelin affect IGF-1?
Yes. Tesamorelin increases GH signaling and can substantially increase circulating IGF-1. Clinical trials have consistently measured IGF-1 as an important pharmacodynamic marker.
6. What is the relationship between tesamorelin and visceral fat?
Tesamorelin has demonstrated a relatively selective effect on visceral adipose tissue in several clinical studies. Research has also examined its effects on liver fat and fat quality.
7. Is tesamorelin FDA approved?
Yes. Its FDA-approved indication is specific to reducing excess abdominal fat in adults with HIV-associated lipodystrophy and does not represent a general obesity indication.
8. Is tesamorelin being studied outside HIV?
Yes. Researchers have examined tesamorelin in other populations, including people with obesity and reduced GH secretion. These studies have investigated visceral fat, metabolic markers, and related outcomes.
9. Is tesamorelin research still ongoing?
Yes. Recent research continues to examine its effects on visceral fat, hepatic fat, body composition, metabolic health, and different HIV treatment populations. For example, a 2024 randomized study examined tesamorelin in people with HIV who were taking integrase inhibitors and reported reductions in visceral and hepatic fat.
Conclusion
Tesamorelin is a synthetic GHRH analog that activates the growth hormone–IGF-1 pathway. Its research profile is particularly notable because clinical trials have repeatedly examined its effects on visceral adipose tissue and related body-composition measures.
The evidence is strongest in people with HIV-associated lipodystrophy. A 2026 meta-analysis of five randomized controlled trials found significant reductions in visceral adipose tissue, hepatic fat, trunk fat, and waist circumference, along with increased lean body mass.
Clinical studies also show an important limitation: reductions in visceral adipose tissue can diminish after tesamorelin exposure is discontinued. In a 52-week study, VAT reductions remained during continued tesamorelin exposure but were lost after discontinuation.
Overall, tesamorelin provides a well-studied example of how GHRH receptor activation can influence endogenous GH secretion, IGF-1 signaling, and visceral adipose tissue. Future research can help clarify its broader metabolic effects, long-term safety, and potential applications beyond the populations already studied.
References
- https://pubmed.ncbi.nlm.nih.gov/18057338/
- https://pubmed.ncbi.nlm.nih.gov/25038357/
- https://en.wikipedia.org/wiki/Tesamorelin
- https://pubchem.ncbi.nlm.nih.gov/compound/Tesamorelin
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022505s020lbl.pdf
- https://pubmed.ncbi.nlm.nih.gov/20943777/
- https://pubmed.ncbi.nlm.nih.gov/23015655/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC8243807/
- https://pubmed.ncbi.nlm.nih.gov/28617838/
- https://pubmed.ncbi.nlm.nih.gov/41545261/
- https://pubmed.ncbi.nlm.nih.gov/33756511/
- https://pubmed.ncbi.nlm.nih.gov/21115997/
